Literature DB >> 9295186

The apparent antipsychotic action of the 5-HT2a receptor antagonist M100907 in a mouse model of schizophrenia is counteracted by ritanserin. (Rapid communication).

P Martin1, N Waters, A Carlsson, M L Carlsson.   

Abstract

The apparent antipsychotic action of the selective 5-HT2a receptor antagonist M100907 in MK-801-treated NMRI mice was shown to be markedly counteracted by the 5-HT2a/2c receptor antagonist ritanserin. The mechanism of action and potential implications are discussed.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9295186     DOI： 10.1007/BF01277672

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN： 0300-9564            Impact factor:   3.575


  13 in total

Review 1.  Gaps and peculiarities in 5-HT2 receptor studies.

Authors:  J E Leysen
Journal:  Neuropsychopharmacology       Date:  1990 Oct-Dec       Impact factor: 7.853

Review 2.  5-HT2 receptor subtypes: a family re-united?

Authors:  G Baxter; G Kennett; F Blaney; T Blackburn
Journal:  Trends Pharmacol Sci       Date:  1995-03       Impact factor: 14.819

3.  The selective 5-HT2A receptor antagonist MDL 100,907 counteracts the psychomotor stimulation ensuing manipulations with monoaminergic, glutamatergic or muscarinic neurotransmission in the mouse--implications for psychosis.

Authors:  M L Carlsson
Journal:  J Neural Transm Gen Sect       Date:  1995

Review 4.  The concept of selectivity in 5-HT receptor research.

Authors:  I van Wijngaarden; M T Tulp; W Soudijn
Journal:  Eur J Pharmacol       Date:  1990-06-12       Impact factor: 4.432

5.  Receptor-binding properties in vitro and in vivo of ritanserin: A very potent and long acting serotonin-S2 antagonist.

Authors:  J E Leysen; W Gommeren; P Van Gompel; J Wynants; P F Janssen; P M Laduron
Journal:  Mol Pharmacol       Date:  1985-06       Impact factor: 4.436

6.  The anticonvulsant MK-801 is a potent N-methyl-D-aspartate antagonist.

Authors:  E H Wong; J A Kemp; T Priestley; A R Knight; G N Woodruff; L L Iversen
Journal:  Proc Natl Acad Sci U S A       Date:  1986-09       Impact factor: 11.205

7.  Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile.

Authors:  J H Kehne; B M Baron; A A Carr; S F Chaney; J Elands; D J Feldman; R A Frank; P L van Giersbergen; T C McCloskey; M P Johnson; D R McCarty; M Poirot; Y Senyah; B W Siegel; C Widmaier
Journal:  J Pharmacol Exp Ther       Date:  1996-05       Impact factor: 4.030

8.  Alterations in extracellular and tissue levels of biogenic amines in rat brain induced by the serotonin2 receptor antagonist, ritanserin.

Authors:  L L Devaud; E B Hollingsworth; B R Cooper
Journal:  J Neurochem       Date:  1992-10       Impact factor: 5.372

9.  Ritanserin, a selective 5-HT2/1C antagonist, and negative symptoms in schizophrenia. A placebo-controlled double-blind trial.

Authors:  S J Duinkerke; P A Botter; A A Jansen; P A van Dongen; A J van Haaften; A J Boom; J H van Laarhoven; H L Busard
Journal:  Br J Psychiatry       Date:  1993-10       Impact factor: 9.319

10.  Evidence for biochemical heterogeneity in schizophrenia: a multivariate study of monoaminergic indices in human post-mortal brain tissue.

Authors:  L O Hansson; N Waters; B Winblad; C G Gottfries; A Carlsson
Journal:  J Neural Transm Gen Sect       Date:  1994
View more
  4 in total

1.  F15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. II. Activity in models of positive symptoms of schizophrenia.

Authors:  R Depoortère; L Bardin; A L Auclair; M S Kleven; E Prinssen; F Colpaert; B Vacher; A Newman-Tancredi
Journal:  Br J Pharmacol       Date:  2007-03-20       Impact factor: 8.739

2.  Blockade of serotonin 2A receptors prevents PCP-induced attentional performance deficit and CREB phosphorylation in the dorsal striatum of DBA/2 mice.

Authors:  Laura Pozzi; Barbara Greco; Giuseppina Sacchetti; Giampaolo Leoni; Roberto W Invernizzi; Mirjana Carli
Journal:  Psychopharmacology (Berl)       Date:  2009-12-08       Impact factor: 4.530

Review 3.  The role of serotonin in the NMDA receptor antagonist models of psychosis and cognitive impairment.

Authors:  Herbert Y Meltzer; Masakuni Horiguchi; Bill W Massey
Journal:  Psychopharmacology (Berl)       Date:  2011-01-08       Impact factor: 4.530

4.  Modulation of midbrain dopamine neurotransmission by serotonin, a versatile interaction between neurotransmitters and significance for antipsychotic drug action.

Authors:  J E Olijslagers; T R Werkman; A C McCreary; C G Kruse; W J Wadman
Journal:  Curr Neuropharmacol       Date:  2006-01       Impact factor: 7.363
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.